In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

www.tevapharm.com

Latest From Teva Pharmaceutical Industries Ltd.

Bookmark
  • News

Talks Must Start Now On New Irish Drug Supply Pact

By Penelope MacRae

An industry group representing Ireland’s generic-and-biosimilar makers says talks “need to start now” on a new national medicine supply accord to create more affordable access to life-saving drugs, with the association’s members at the negotiating table.

Ireland Regulation
Bookmark
  • Analysis

Drug Pricing Hearing Takes A Partisan Turn As Gilead’s O’Day Holds His Own

By Cathy Kelly
Republicans took off the gloves at House oversight hearing on PrEP, arguing Democrats are more interested in scoring political points than seeking policy solutions to high drug costs.
Pricing Debate Legislation
Bookmark
  • News

Teva Takes A Further Hit On Value Of Actavis

By David Wallace

Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took over Actavis in 2016. Meanwhile, sales slid by 15% to $4.3bn in the first quarter.

Sales & Earnings Strategy
Bookmark
  • Analysis

Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market

By Anju Ghangurde

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By